Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $54.00 Average Target Price from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned an average recommendation of “Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $54.00.

Several research firms have commented on DNTH. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an “outperform” rating in a research note on Thursday, August 21st. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Robert W. Baird decreased their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a research report on Tuesday, May 13th. Finally, William Blair assumed coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an “outperform” rating for the company.

Dianthus Therapeutics Stock Up 7.5%

NASDAQ DNTH opened at $26.50 on Wednesday. The company has a fifty day moving average of $21.27 and a two-hundred day moving average of $20.08. The firm has a market capitalization of $853.04 million, a price-to-earnings ratio of -8.15 and a beta of 1.46. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. Equities research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC lifted its position in shares of Dianthus Therapeutics by 3.1% during the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock worth $313,000 after purchasing an additional 433 shares during the last quarter. ADAR1 Capital Management LLC raised its holdings in shares of Dianthus Therapeutics by 3.4% in the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company’s stock valued at $332,000 after acquiring an additional 602 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Dianthus Therapeutics by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company’s stock valued at $1,336,000 after acquiring an additional 748 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Dianthus Therapeutics by 0.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company’s stock valued at $3,049,000 after acquiring an additional 1,081 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.